通鼎互聯(002491.SZ):擬687.45萬元受讓計大囡持有的通鼎寬帶1.27%的股權
格隆匯10月9日丨通鼎互聯(002491.SZ)公佈,公司於2023年9月28日召開了第五屆董事會第二十六次會議(臨時會議),審議通過了《關於以現金收購通鼎寬帶1.27%股權的議案》。根據公司戰略規劃和經營發展的需要,公司擬與計大囡簽署協議,收購自然人計大囡所持江蘇通鼎寬帶有限公司(以下簡稱"通鼎寬帶")1.27%股權。通鼎寬帶在2023年6月30日的股東全部權益價值為人民幣60,144.08萬元,折算1.27%股東權益價值為人民幣763.83萬元,在此基礎上雙方協商確定,公司擬以九折後的金額人民幣687.45萬元受讓計大囡持有的通鼎寬帶1.27%的股權。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.